Increase your likelihood of successful pregnancy by pairing Preimplantation Genetic Testing for Aneuploidy (PGT-A) with IVF treatment. PGT-A (often called PGS, or preimplantation genetic screening) assesses the number of chromosomes in each IVF embryo to identify any embryos that may be chromosomally abnormal. By purposefully selecting chromosomally normal embryos for implantation, you can greatly expand your prospects of a successful IVF treatment and a healthy pregnancy.
PGT-A is a test designed to look at the DNA (genetic information) within individual embryos to help identify the most suitable embryo for a successful IVF pregnancy. This genetic information is stored within rod-shaped structures known as chromosomes, which are important for one’s growth and development. Normally, embryos contain 46 chromosomes (23 pairs). Such embryos are “euploid” and have a higher chance of resulting in a successful pregnancy. Embryos containing an abnormal number of chromosomes are “aneuploid.” Aneuploid embryos may not successfully implant in the womb, or they may result in miscarriage or the birth of the child with a genetic condition.
A few cells are gently biopsied from each IVF embryo by your care team.
The cells are shipped to our lab at Fulgent.
We perform PGT-A chromosome analysis on all 46 chromosomes.
We issue a full report to your care team within 1-2 weeks of receiving samples.
You and your care team can choose the healthiest embryos for implantation.
